Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2668 | Propofol Wiki | 0.71 |
drug155 | Activity Wiki | 0.71 |
drug1718 | Intravenous drug Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.11 |
D013577 | Syndrome NIH | 0.07 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this trial is to study the effect of initial temporary sevoflurane sedation on mortality and persistent organ dysfunction (POD) in survivors at day 28 after ICU admission in the population of patients suffering from COVID-19 ARDS.
Description: The effect of sevoflurane application on mortality (rate of patients that does not survive 28 days) and persistent organ dysfunction (rate of patients surviving with a persistent organ failure at day 28) will be assessed. Organ failures are defined as pulmonary failure (necessity of ventilation); cardiovascular failure (need of vasopressors), retail failure (need of renal replacement therapy)
Measure: Composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28 Time: 28 daysDescription: The effect of sevoflurane application on the length of stay at ICU will be determined.
Measure: Length of stay ICU Time: 28 daysDescription: The impact of sevoflurane on the course of inflammatory markers will be evaluated (pro-calcitonin, PCT; c-reactive protein, CRP; interleukin 6, IL-6; monocyte chemoattractant protein 1, MCP-1)
Measure: Plasma Inflammatory markers Time: 8 daysDescription: The effect of sevoflurane application on the length of stay at hospital will be determined.
Measure: Length of stay at hospital Time: 28 daysDescription: Sex-related differences in complications will be assessed
Measure: Sex-related differences in complications Time: 28 daysIt is a multicenter, national, randomized 1:1 ratio, controlled, parallel, open study. Patients with severe ARDS-CoVid19 will be included in the trial within the first 24 hours. Patients will be randomized to one of the treatment groups: - SEV group: 25 patients with Sevoflurane sedation by inhalation, starting at 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved (BIS 40-50) - PRO group: 25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
Description: To evaluate the effect of 48-hour treatment with inhaled sevoflurane on arterial oxygenation, assessed by PaO2/FiO2 on day two, in patients with ARDS-CoVid19
Measure: PaO2/FiO2 Time: Day 2Description: To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19
Measure: TNFα Time: Day 2Description: To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19
Measure: IL-1b Time: Day 2Description: To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19
Measure: IL-6 Time: Day 2Description: To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19
Measure: IL-8 Time: Day 2Description: To evaluate the 30-day mortality.
Measure: Mortality Time: Day 30Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports